Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients With Moderate to Severe Plaque Psoriasis

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients With Moderate to Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bazlitoran (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Aceragen; Idera Pharmaceuticals

    • Most Recent Events

    • 24 Mar 2015 Results presented at the 73rd Annual Meeting of the American Academy of Dermatology.
    • 08 Dec 2014 According to an Idera Pharmaceuticals media release, clinical safety results of this and other trial (see profile 224829) were presented at 56th Annual Meeting of the American Society of Hematology .
    • 18 Jun 2014 New source identified and integrated (European Clinical Trials Database: EudraCT2013-000164-28)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top